Verici Dx plc (LSE:VRCI), the AIM-quoted transplant diagnostics company, has announced a proposed fundraise and entered a Capital Access Window, pausing trading in its shares pending the outcome. The news came alongside half-year results showing Tutivia testing Revenue up 53% and period-end cash of $2.4 million.
What Verici Dx announced
On the evening of 30 September 2026, Verici Dx said it intends to undertake a proposed fundraising with institutional and other investors. Singer Capital Markets and Oberon Investments are acting as joint bookrunners and brokers. The company said trading in its ordinary shares on AIM would enter a Capital Access Window from 7:30am on 1 October 2026, with trading paused "until a further announcement is made regarding the outcome of the Proposed Fundraise."
No price or size was given. The company said the issue price and the final number of new ordinary shares will be determined once the bookbuild is complete.
Why the company is returning to the market
The fundraise follows a £2.6 million gross ($3.4 million) share placing completed in June 2026. According to the company, the June money provided funding to expand the commercial team, and the new raise is intended to "maintain these growth plans". The board said it was greatly encouraged by the support expressed by certain key shareholders to date.
For AIM stocks at an early commercial stage, a second raise within a few months typically reflects the cash needs of scaling a sales operation. Verici's half-year report shows why funding is a central question.
Half-year results in detail
For the six months to 30 June 2026, revenue was $1.8 million, compared with $1.9 million in the first half of 2025. Tutivia testing revenue rose 53% to $1.77 million, but the prior-year period included $0.75 million of licensing income from Thermo Fisher, with none in the latest half. The adjusted EBITDA loss widened to $3.5 million from $2.8 million, and the operating cash outflow was $3.8 million, against $3.5 million a year earlier. Cash stood at $2.4 million at 30 June 2026, down from $3.3 million at 31 December 2025.
Operationally, the company reported 32 transplant centres onboarded during the half, with 35 now operational, which it says represents 23% of annual US kidney transplants. It cited an average reimbursement rate of $2,300 per test, a contracted pricing agreement with Blue Cross and Blue Shield of Illinois, and an additional Proprietary Laboratory Analyses code from the AMA for Protega. Keith Gilliard was appointed Senior Sales Director.
Chief executive Sara Barrington said: "H1 2026 has been a positive and progressive period for Verici".
Risks for shareholders
The main uncertainties are the pricing and size of the fundraise, which remain undisclosed, and the potential dilution for existing holders. Losses and cash outflow increased year on year, and period-end cash of $2.4 million sits below the $3.8 million operating outflow recorded in the half. Commercial progress also depends on continued test adoption and reimbursement in the US.
What investors may watch next
The next announcement should confirm the fundraise outcome and the resumption of trading. Beyond that, the company says Q3 2026 is on track for a 53% year-on-year increase in test orders, and it expects further growth in Q4 from an expanded sales team. It also anticipates launching Transcriptx by year-end, with revenue streams from Protega and PTRA expected in FY 2027.
Where this leaves the AIM-quoted diagnostics group
Verici Dx is pairing clear growth in Tutivia testing with a fresh call on shareholders. For those following UK diagnostics shares, the bookbuild result and subsequent order data are the next reference points on the London Stock Exchange.






Please wait processing your request...